AngioDynamics' fiscal Q2'25 results exceeded expectations, with Med Tech growing 25% and delivering better gross margins, boosting confidence in achieving high single-digit revenue growth and double-digit EBITDA margins in time. Clinical data for AlphaVac and NanoKnife were positive relative to established standards of care, suggesting potentially competitive offerings in the pulmonary embolism and prostate cancer markets if management can execute. Auryon, AlphaVac, and NanoKnife all offer double-digit growth potential, but sales execution against larger entrenched rivals is not going to be easy and the Med Device business offers limited potential.
Canaccord raised the firm's price target on AngioDynamics to $15 from $12 and keeps a Buy rating on the shares. AngioDynamics reported one of its strongest quarters in recent memory, the analyst tells investors in a research note. The firm back-end loaded its NanoKnife expectations for this fiscal year, but thinks in the long-term it could provide significant growth for AngioDynamics. It sees thrombectomy acceleration today with improving profitability.
ANGO registers overall strong top-line results on a pro-forma basis in second-quarter fiscal 2025, driven by strength in the Med Tech business.
AngioDynamics, Inc.'s Q2 2025 earnings beat expectations, with non-GAAP EPS at -$0.04 and revenue at $73.02 million, driving a 35% stock surge. Med Tech division shines, with 25% revenue growth and key products like Auryon, AlphaVac, and AngioVac showing strong performance and market acceptance. NanoKnife's FDA clearance and promising clinical trials highlight its potential in prostate cancer treatment, contributing to a 23.1% rise in disposable revenue.
AngioDynamics, Inc. (NASDAQ:ANGO ) Q2 2025 Earnings Conference Call January 8, 2025 8:00 AM ET Company Participants Jim Clemmer - President and Chief Executive Officer Stephen Trowbridge - Executive Vice President and Chief Financial Officer Conference Call Participants John Young - Canaccord Genuity Steven Lichtman - Oppenheimer Yi Chen - H.C. Wainwright Operator Good morning and welcome to the AngioDynamics Fiscal Year 2025 Second Quarter Earnings Call.
AngioDynamics (ANGO) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.05 per share a year ago.
AngioDynamics' latest regulatory approval is likely to pave the way for an alternative to conventional radical surgery and improve patient outcomes.
AngioDynamics (ANGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
The consensus price target hints at a 94.3% upside potential for AngioDynamics (ANGO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ANGO enhances its offerings and expands the breadth of its products and services. However, macro challenges are likely to continue to hurt its performance.
AngioDynamics announces the receipt of CPT Category I code for IRE technology.
AngioDynamics (ANGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.